시장보고서
상품코드
1812385

안과 의약품 시장

Ophthalmic Drugs Market

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 234 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

안과 의약품 시장 - 조사 범위

TMR의 조사 보고서 '세계의 안과 의약품 시장'은 2025-2035년 예측 기간 동안 시장 지표에 대한 가치 있는 인사이트를 얻기 위해 과거 및 현재의 성장 동향과 기회를 연구합니다. 2025년 기준 연도, 2035년 예측연도로 2025-2035년 세계의 안과 의약품 시장 수익과 예측을 제공합니다. 또한 2025-2035년 세계의 안과 의약품 시장 연평균 성장률(CAGR%)도 제공합니다.

본 보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더, 의견 형성자들과 인터뷰를 실시했습니다. 2차 연구는 주요 업체들의 제품 문헌, 연차 보고서, 보도 자료 및 관련 문서를 참조하여 안과 의약품 시장을 파악했습니다.

시장 현황
시장 매출(2024년) 354억 달러
시장 매출(2035년) 679억 달러
CAGR 6.1%

본 보고서는 세계의 안과 의약품 시장 경쟁 구도를 조사했습니다. 세계의 안과 의약품 시장에서 활동하는 주요 업체들을 식별하고, 각 업체를 다양한 속성 측면에서 프로파일링했습니다. 기업 개요, 재무 현황, 최근 동향, SWOT 분석은 본 보고서에서 프로파일링된 세계의 안과 의약품 시장 참여 기업 속성입니다.

세계의 안과 의약품 시장 보고서에서 다루는 주요 질문

  • 세계의 안과 의약품 시장 비즈니스 기회는 무엇인가?
  • 시장의 주요 촉진요인, 시장 성장 억제요인, 기회, 위협은 무엇인가?
  • 예측 기간 동안 가장 빠른 CAGR로 성장하는 지역 시장은 어디인가?
  • 2035년 세계에서 가장 높은 수익을 올릴 것으로 예상되는 부문은 무엇인가?
  • 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상되는 부문은 무엇인가?
  • 세계 시장에서 사업 전개하는 각 기업 시장 포지션은 무엇인가?

안과 의약품 시장 - 조사 목적 및 조사 방법

본 조사 보고서는 세계의 안과 의약품 시장에 대해 연구 및 분석한 보고서입니다. 본 보고서는 연구 목적과 시장 내 주요 공급업체 및 유통업체, 제품 승인 관련 규제 환경에 대한 상세한 설명을 제공합니다.

독해 편의성을 위해 보고서는 장별 구성으로 편성되었으며, 각 부분은 소단위로 세분화되었습니다. 보고서는 적절히 배치된 방대한 그래프 및 표를 포함합니다. 주요 부문의 실제 및 예상 값을 시각적으로 표현한 내용은 독자에게 시각적 매력을 제공합니다. 이는 또한 과거와 예측 기간 말 시점의 주요 부문 시장 점유율 비교를 가능하게 합니다.

본 보고서에서는 세계의 안과 의약품 시장을 제품, 최종 사용자, 지역별로 분석했습니다. 각 기준별 주요 부문을 심층 연구하였으며, 2035년 말 기준 각 부문의 시장 점유율을 제시합니다. 이러한 가치 있는 인사이트는 시장 관계자들이 세계의 안과 의약품 시장에 대한 투자 결정을 내리는 데 유용한 정보를 제공합니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

  • 소개
  • 개요
  • 시장 역학
  • 세계의 안과 의약품 시장 분석과 예측(2020-2035년)

제5장 주요 인사이트

  • 주요 지역 및 국가 의료비 지출
  • 안과 의약품의 최근 진보
  • 주요 지역 및 국가에 있어서의 안질환의 역학
  • 안과 의약품의 가격 동향
  • 주요 지역 및 국가 규제 시나리오
  • Porter's Five Forces 분석
  • PESTEL 분석
  • 밸류체인 분석
  • 최종 사용자를 위한 주요 구매 지표
  • 신규 시장 참가자를 위한 시장 개척 전략
  • 주요 업계 이벤트(파트너십, 콜라보레이션, 제품 승인, 합병 및 인수)
  • 주요 경쟁이 제공하는 주요 제품 벤치 마크

제6장 세계 시장 분석과 예측 : 약제 유형별

  • 소개 및 정의
  • 주요 조사 결과 및 진전
  • 시장 매출 예측 : 약제 유형별(2020-2035년)
    • 항알레르기제
    • 항감염제
    • 비스테로이드제
    • 항VEGF 의약품
      • 앱타머
      • 항체(단일클론항체 및 이중특이성 항체)
      • 융합 단백질
    • 유전자 치료제
    • 기타
  • 시장의 매력 : 약제 유형별

제7장 세계 시장 분석과 예측 : 투여 경로별

  • 소개 및 정의
  • 주요 조사 결과 및 진전
  • 시장 매출 예측 : 투여 경로별(2020-2035년)
    • 국소
    • 안구 내
    • 기타
  • 시장의 매력 : 투여 경로별

제8장 세계 시장 분석과 예측 : 제형별

  • 소개 및 정의
  • 주요 조사 결과 및 진전
  • 시장 매출 예측 : 제형별(2020-2035년)
    • 점안액
    • 연고
    • 현탁액 및 용액
    • 기타
  • 시장의 매력 : 제형별

제9장 세계 시장 분석과 예측 : 제품 유형별

  • 소개 및 정의
  • 주요 조사 결과 및 진전
  • 시장 매출 예측 : 제품 유형별(2020-2035년)
    • 처방약
    • 일반
  • 시장의 매력 : 제품 유형별

제10장 세계 시장 분석과 예측 : 적응증별

  • 소개 및 정의
  • 주요 조사 결과 및 진전
  • 시장 매출 예측 : 적응증별(2020-2035년)
    • 녹내장
    • 안구건조증
    • 노화 황반 변성증
    • 당뇨병 망막증
    • 결막염
    • 백내장
    • 망막 박리
    • 기타
  • 시장의 매력 : 적응증별

제11장 세계 시장 분석과 예측 : 유통 채널별

  • 소개 및 정의
  • 주요 조사 결과 및 진전
  • 시장 매출 예측 : 유통 채널별(2020-2035년)
    • 병원 약국
    • 소매 약국
    • 온라인 약국
  • 시장의 매력 : 유통 채널별

제12장 세계 시장 분석과 예측 : 지역별

  • 주요 조사 결과
  • 시장 매출 예측 : 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장의 매력 : 지역별

제13장 북미 시장 분석과 예측

  • 미국
  • 캐나다

제14장 유럽 시장 분석과 예측

  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 스위스
  • 네덜란드
  • 기타 유럽

제15장 아시아태평양 시장 분석과 예측

  • 중국
  • 인도
  • 일본
  • 한국
  • 호주 및 뉴질랜드
  • 기타 아시아태평양

제16장 라틴아메리카 시장 분석과 예측

  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타 라틴아메리카

제17장 중동 및 아프리카 시장 분석과 예측

  • GCC 국가
  • 남아프리카
  • 기타 중동 및 아프리카

제18장 경쟁 구도

  • 시장 기업 : 경쟁 매트릭스(기업 등급별, 규모별)
  • 시장 점유율 분석기업별(2024년)
  • 기업 프로파일
    • Alcon Inc.
    • Novartis AG
    • Bausch Lomb.
    • Merck & Co., Inc.
    • Regeneron Pharmaceuticals Inc.
    • Coherus BioSciences, Inc.
    • Pfizer Inc.
    • AbbVie
    • RIBOMIC
    • Santen Pharmaceutical Co., Ltd.
    • Cipla Limited
    • Lupin Pharmaceuticals, Inc.
    • Ocular Therapeutix, Inc.
    • Novaliq GmbH
    • ZEXUS PHARMA
    • Grevis Pharmaceuticals Pvt. Ltd.
HBR 25.09.29

Ophthalmic Drugs Market- Scope of Report

TMR's report on the global Ophthalmic Drugs Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Ophthalmic Drugs Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Ophthalmic Drugs Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Ophthalmic Drugs Market .

Market Snapshot
Market Value in 2024US$ 35.4 Bn
Market Value in 2035US$ 67.9 Bn
CAGR6.1%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Ophthalmic Drugs Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Ophthalmic Drugs Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Ophthalmic Drugs Market .

The report delves into the competitive landscape of the global Ophthalmic Drugs Market . Key players operating in the global Ophthalmic Drugs Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Ophthalmic Drugs Marketprofiled in this report.

Key Questions Answered in Global Ophthalmic Drugs MarketReport:

  • What are the opportunities in the global Ophthalmic Drugs Market ?
  • What are the major drivers, restraints, opportunities, and threats in the Market ?
  • Which regional Market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the Market positions of different companies operating in the global Market ?

Ophthalmic Drugs Market- Research Objectives and Research Approach

The comprehensive report on the global Ophthalmic Drugs Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Ophthalmic Drugs Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Ophthalmic Drugs Market .

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Ophthalmic Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Ophthalmic Drugs Market Analysis and Forecasts, 2020 to 2035
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Healthcare Expenditure across Key Regions / Countries
  • 5.2. Recent Advancements in Ophthalmic Medications
  • 5.3. Epidemiology of Ophthalmic Disorders across Key Regions / Countries
  • 5.4. Pricing Trends for Ophthalmic Drugs
  • 5.5. Regulatory Scenario across Key Regions / Countries
  • 5.6. PORTER's Five Forces Analysis
  • 5.7. PESTEL Analysis
  • 5.8. Value Chain Analysis
  • 5.9. Key Purchase Metrics for End-users
  • 5.10. Go-to-Market Strategy for New Market Entrants
  • 5.11. Key Industry Events (Partnerships, Collaborations, Product approvals, mergers & acquisitions)
  • 5.12. Benchmarking of Key Products Offered by the Leading Competitors

6. Global Ophthalmic Drugs Market Analysis and Forecasts, By Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Drug Type, 2020 to 2035
    • 6.3.1. Anti-Allergy Drugs
    • 6.3.2. Anti-infective Drugs
    • 6.3.3. Nonsteroidal Drugs
    • 6.3.4. Anti-VEGF Drugs
      • 6.3.4.1. Aptamer
      • 6.3.4.2. Antibodies (mAb & Bispecific Antibody)
      • 6.3.4.3. Fusion Protein
    • 6.3.5. Gene Therapy Drugs
    • 6.3.6. Others
  • 6.4. Market Attractiveness By Drug Type

7. Global Ophthalmic Drugs Market Analysis and Forecasts, By Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Route of Administration, 2020 to 2035
    • 7.3.1. Topical
    • 7.3.2. Intraocular
    • 7.3.3. Others
  • 7.4. Market Attractiveness By Route of Administration

8. Global Ophthalmic Drugs Market Analysis and Forecasts, By Dosage Form

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Dosage Form, 2020 to 2035
    • 8.3.1. Gel
    • 8.3.2. Drop
    • 8.3.3. Ointment
    • 8.3.4. Suspension & Solutions
    • 8.3.5. Others
  • 8.4. Market Attractiveness By Dosage Form

9. Global Ophthalmic Drugs Market Analysis and Forecasts, By Product Type

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By Product Type, 2020 to 2035
    • 9.3.1. Prescription Drugs
    • 9.3.2. Over-the-Counter
  • 9.4. Market Attractiveness By Product Type

10. Global Ophthalmic Drugs Market Analysis and Forecasts, By Indication

  • 10.1. Introduction & Definition
  • 10.2. Key Findings / Developments
  • 10.3. Market Value Forecast By Indication, 2020 to 2035
    • 10.3.1. Glaucoma
    • 10.3.2. Dry Eye Disease
    • 10.3.3. Age-Related Macular Degeneration
    • 10.3.4. Diabetic Retinopathy
    • 10.3.5. Pink Eye
    • 10.3.6. Cataracts
    • 10.3.7. Retinal Detachment
    • 10.3.8. Others
  • 10.4. Market Attractiveness By Indication

11. Global Ophthalmic Drugs Market Analysis and Forecasts, By Distribution Channel

  • 11.1. Introduction & Definition
  • 11.2. Key Findings / Developments
  • 11.3. Market Value Forecast By Distribution Channel, 2020 to 2035
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
  • 11.4. Market Attractiveness By Distribution Channel

12. Global Ophthalmic Drugs Market Analysis and Forecasts, By Region

  • 12.1. Key Findings
  • 12.2. Market Value Forecast By Region
    • 12.2.1. North America
    • 12.2.2. Europe
    • 12.2.3. Asia Pacific
    • 12.2.4. Latin America
    • 12.2.5. Middle East & Africa
  • 12.3. Market Attractiveness By Region

13. North America Ophthalmic Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Type, 2020 to 2035
    • 13.2.1. Anti-Allergy Drugs
    • 13.2.2. Anti-infective Drugs
    • 13.2.3. Nonsteroidal Drugs
    • 13.2.4. Anti-VEGF Drugs
      • 13.2.4.1. Aptamer
      • 13.2.4.2. Antibodies (mAb & Bispecific Antibody)
      • 13.2.4.3. Fusion Protein
    • 13.2.5. Gene Therapy Drugs
    • 13.2.6. Others
  • 13.3. Market Value Forecast By Route of Administration, 2020 to 2035
    • 13.3.1. Topical
    • 13.3.2. Intraocular
    • 13.3.3. Others
  • 13.4. Market Value Forecast By Dosage Form, 2020 to 2035
    • 13.4.1. Gel
    • 13.4.2. Drop
    • 13.4.3. Ointment
    • 13.4.4. Suspension & Solutions
    • 13.4.5. Others
  • 13.5. Market Value Forecast By Product Type, 2020 to 2035
    • 13.5.1. Prescription Drugs
    • 13.5.2. Over-the-Counter
  • 13.6. Market Value Forecast By Indication, 2020 to 2035
    • 13.6.1. Glaucoma
    • 13.6.2. Dry Eye Disease
    • 13.6.3. Age-Related Macular Degeneration
    • 13.6.4. Diabetic Retinopathy
    • 13.6.5. Pink Eye
    • 13.6.6. Cataracts
    • 13.6.7. Retinal Detachment
    • 13.6.8. Others
  • 13.7. Market Value Forecast By Distribution Channel, 2020 to 2035
    • 13.7.1. Hospital Pharmacies
    • 13.7.2. Retail Pharmacies
    • 13.7.3. Online Pharmacies
  • 13.8. Market Value Forecast By Country , 2020 to 2035
    • 13.8.1. U.S.
    • 13.8.2. Canada
  • 13.9. Market Attractiveness Analysis
    • 13.9.1. By Drug Type
    • 13.9.2. By Route of Administration
    • 13.9.3. By Dosage Form
    • 13.9.4. By Product Type
    • 13.9.5. By Indication
    • 13.9.6. By Distribution Channel
    • 13.9.7. By Country

14. Europe Ophthalmic Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Drug Type, 2020 to 2035
    • 14.2.1. Anti-Allergy Drugs
    • 14.2.2. Anti-infective Drugs
    • 14.2.3. Nonsteroidal Drugs
    • 14.2.4. Anti-VEGF Drugs
      • 14.2.4.1. Aptamer
      • 14.2.4.2. Antibodies (mAb & Bispecific Antibody)
      • 14.2.4.3. Fusion Protein
    • 14.2.5. Gene Therapy Drugs
    • 14.2.6. Others
  • 14.3. Market Value Forecast By Route of Administration, 2020 to 2035
    • 14.3.1. Topical
    • 14.3.2. Intraocular
    • 14.3.3. Others
  • 14.4. Market Value Forecast By Dosage Form, 2020 to 2035
    • 14.4.1. Gel
    • 14.4.2. Drop
    • 14.4.3. Ointment
    • 14.4.4. Suspension & Solutions
    • 14.4.5. Others
  • 14.5. Market Value Forecast By Product Type, 2020 to 2035
    • 14.5.1. Prescription Drugs
    • 14.5.2. Over-the-Counter
  • 14.6. Market Value Forecast By Indication, 2020 to 2035
    • 14.6.1. Glaucoma
    • 14.6.2. Dry Eye Disease
    • 14.6.3. Age-Related Macular Degeneration
    • 14.6.4. Diabetic Retinopathy
    • 14.6.5. Pink Eye
    • 14.6.6. Cataracts
    • 14.6.7. Retinal Detachment
    • 14.6.8. Others
  • 14.7. Market Value Forecast By Distribution Channel, 2020 to 2035
    • 14.7.1. Hospital Pharmacies
    • 14.7.2. Retail Pharmacies
    • 14.7.3. Online Pharmacies
  • 14.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
    • 14.8.1. Germany
    • 14.8.2. UK
    • 14.8.3. France
    • 14.8.4. Italy
    • 14.8.5. Spain
    • 14.8.6. Switzerland
    • 14.8.7. The Netherlands
    • 14.8.8. Rest of Europe
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Drug Type
    • 14.9.2. By Route of Administration
    • 14.9.3. By Dosage Form
    • 14.9.4. By Product Type
    • 14.9.5. By Indication
    • 14.9.6. By Distribution Channel
    • 14.9.7. By Country / Sub-region

15. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Drug Type, 2020 to 2035
    • 15.2.1. Anti-Allergy Drugs
    • 15.2.2. Anti-infective Drugs
    • 15.2.3. Nonsteroidal Drugs
    • 15.2.4. Anti-VEGF Drugs
      • 15.2.4.1. Aptamer
      • 15.2.4.2. Antibodies (mAb & Bispecific Antibody)
      • 15.2.4.3. Fusion Protein
    • 15.2.5. Gene Therapy Drugs
    • 15.2.6. Others
  • 15.3. Market Value Forecast By Route of Administration, 2020 to 2035
    • 15.3.1. Topical
    • 15.3.2. Intraocular
    • 15.3.3. Others
  • 15.4. Market Value Forecast By Dosage Form, 2020 to 2035
    • 15.4.1. Gel
    • 15.4.2. Drop
    • 15.4.3. Ointment
    • 15.4.4. Suspension & Solutions
    • 15.4.5. Others
  • 15.5. Market Value Forecast By Product Type, 2020 to 2035
    • 15.5.1. Prescription Drugs
    • 15.5.2. Over-the-Counter
  • 15.6. Market Value Forecast By Indication, 2020 to 2035
    • 15.6.1. Glaucoma
    • 15.6.2. Dry Eye Disease
    • 15.6.3. Age-Related Macular Degeneration
    • 15.6.4. Diabetic Retinopathy
    • 15.6.5. Pink Eye
    • 15.6.6. Cataracts
    • 15.6.7. Retinal Detachment
    • 15.6.8. Others
  • 15.7. Market Value Forecast By Distribution Channel, 2020 to 2035
    • 15.7.1. Hospital Pharmacies
    • 15.7.2. Retail Pharmacies
    • 15.7.3. Online Pharmacies
  • 15.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
    • 15.8.1. China
    • 15.8.2. India
    • 15.8.3. Japan
    • 15.8.4. South Korea
    • 15.8.5. Australia & New Zealand
    • 15.8.6. Rest of Asia Pacific
  • 15.9. Market Attractiveness Analysis
    • 15.9.1. By Drug Type
    • 15.9.2. By Route of Administration
    • 15.9.3. By Dosage Form
    • 15.9.4. By Product Type
    • 15.9.5. By Indication
    • 15.9.6. By Distribution Channel
    • 15.9.7. By Country / Sub-region

16. Latin America Ophthalmic Drugs Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast By Drug Type, 2020 to 2035
    • 16.2.1. Anti-Allergy Drugs
    • 16.2.2. Anti-infective Drugs
    • 16.2.3. Nonsteroidal Drugs
    • 16.2.4. Anti-VEGF Drugs
      • 16.2.4.1. Aptamer
      • 16.2.4.2. Antibodies (mAb & Bispecific Antibody)
      • 16.2.4.3. Fusion Protein
    • 16.2.5. Gene Therapy Drugs
    • 16.2.6. Others
  • 16.3. Market Value Forecast By Route of Administration, 2020 to 2035
    • 16.3.1. Topical
    • 16.3.2. Intraocular
    • 16.3.3. Others
  • 16.4. Market Value Forecast By Dosage Form, 2020 to 2035
    • 16.4.1. Gel
    • 16.4.2. Drop
    • 16.4.3. Ointment
    • 16.4.4. Suspension & Solutions
    • 16.4.5. Others
  • 16.5. Market Value Forecast By Product Type, 2020 to 2035
    • 16.5.1. Prescription Drugs
    • 16.5.2. Over-the-Counter
  • 16.6. Market Value Forecast By Indication, 2020 to 2035
    • 16.6.1. Glaucoma
    • 16.6.2. Dry Eye Disease
    • 16.6.3. Age-Related Macular Degeneration
    • 16.6.4. Diabetic Retinopathy
    • 16.6.5. Pink Eye
    • 16.6.6. Cataracts
    • 16.6.7. Retinal Detachment
    • 16.6.8. Others
  • 16.7. Market Value Forecast By Distribution Channel, 2020 to 2035
    • 16.7.1. Hospital Pharmacies
    • 16.7.2. Retail Pharmacies
    • 16.7.3. Online Pharmacies
  • 16.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
    • 16.8.1. Brazil
    • 16.8.2. Mexico
    • 16.8.3. Argentina
    • 16.8.4. Rest of Latin America
  • 16.9. Market Attractiveness Analysis
    • 16.9.1. By Drug Type
    • 16.9.2. By Route of Administration
    • 16.9.3. By Dosage Form
    • 16.9.4. By Product Type
    • 16.9.5. By Indication
    • 16.9.6. By Distribution Channel
    • 16.9.7. By Country / Sub-region

17. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast

  • 17.1. Introduction
    • 17.1.1. Key Findings
  • 17.2. Market Value Forecast By Drug Type, 2020 to 2035
    • 17.2.1. Anti-Allergy Drugs
    • 17.2.2. Anti-infective Drugs
    • 17.2.3. Nonsteroidal Drugs
    • 17.2.4. Anti-VEGF Drugs
      • 17.2.4.1. Aptamer
      • 17.2.4.2. Antibodies (mAb & Bispecific Antibody)
      • 17.2.4.3. Fusion Protein
    • 17.2.5. Gene Therapy Drugs
    • 17.2.6. Others
  • 17.3. Market Value Forecast By Route of Administration, 2020 to 2035
    • 17.3.1. Topical
    • 17.3.2. Intraocular
    • 17.3.3. Others
  • 17.4. Market Value Forecast By Dosage Form, 2020 to 2035
    • 17.4.1. Gel
    • 17.4.2. Drop
    • 17.4.3. Ointment
    • 17.4.4. Suspension & Solutions
    • 17.4.5. Others
  • 17.5. Market Value Forecast By Product Type, 2020 to 2035
    • 17.5.1. Prescription Drugs
    • 17.5.2. Over-the-Counter
  • 17.6. Market Value Forecast By Indication, 2020 to 2035
    • 17.6.1. Glaucoma
    • 17.6.2. Dry Eye Disease
    • 17.6.3. Age-Related Macular Degeneration
    • 17.6.4. Diabetic Retinopathy
    • 17.6.5. Pink Eye
    • 17.6.6. Cataracts
    • 17.6.7. Retinal Detachment
    • 17.6.8. Others
  • 17.7. Market Value Forecast By Distribution Channel, 2020 to 2035
    • 17.7.1. Hospital Pharmacies
    • 17.7.2. Retail Pharmacies
    • 17.7.3. Online Pharmacies
  • 17.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
    • 17.8.1. GCC Countries
    • 17.8.2. South Africa
    • 17.8.3. Rest of Middle East & Africa
  • 17.9. Market Attractiveness Analysis
    • 17.9.1. By Drug Type
    • 17.9.2. By Route of Administration
    • 17.9.3. By Dosage Form
    • 17.9.4. By Product Type
    • 17.9.5. By Indication
    • 17.9.6. By Distribution Channel
    • 17.9.7. By Country / Sub-region

18. Competition Landscape

  • 18.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 18.2. Market Share Analysis By Company (2024)
  • 18.3. Company Profiles
    • 18.3.1. Alcon Inc.
      • 18.3.1.1. Company Overview
      • 18.3.1.2. Financial Overview
      • 18.3.1.3. Product Portfolio
      • 18.3.1.4. Business Strategies
      • 18.3.1.5. Recent Developments
    • 18.3.2. Novartis AG
      • 18.3.2.1. Company Overview
      • 18.3.2.2. Financial Overview
      • 18.3.2.3. Product Portfolio
      • 18.3.2.4. Business Strategies
      • 18.3.2.5. Recent Developments
    • 18.3.3. Bausch + Lomb.
      • 18.3.3.1. Company Overview
      • 18.3.3.2. Financial Overview
      • 18.3.3.3. Product Portfolio
      • 18.3.3.4. Business Strategies
      • 18.3.3.5. Recent Developments
    • 18.3.4. Merck & Co., Inc.
      • 18.3.4.1. Company Overview
      • 18.3.4.2. Financial Overview
      • 18.3.4.3. Product Portfolio
      • 18.3.4.4. Business Strategies
      • 18.3.4.5. Recent Developments
    • 18.3.5. Regeneron Pharmaceuticals Inc.
      • 18.3.5.1. Company Overview
      • 18.3.5.2. Financial Overview
      • 18.3.5.3. Product Portfolio
      • 18.3.5.4. Business Strategies
      • 18.3.5.5. Recent Developments
    • 18.3.6. Coherus BioSciences, Inc.
      • 18.3.6.1. Company Overview
      • 18.3.6.2. Financial Overview
      • 18.3.6.3. Product Portfolio
      • 18.3.6.4. Business Strategies
      • 18.3.6.5. Recent Developments
    • 18.3.7. Pfizer Inc.
      • 18.3.7.1. Company Overview
      • 18.3.7.2. Financial Overview
      • 18.3.7.3. Product Portfolio
      • 18.3.7.4. Business Strategies
      • 18.3.7.5. Recent Developments
    • 18.3.8. AbbVie
      • 18.3.8.1. Company Overview
      • 18.3.8.2. Financial Overview
      • 18.3.8.3. Product Portfolio
      • 18.3.8.4. Business Strategies
      • 18.3.8.5. Recent Developments
    • 18.3.9. RIBOMIC
      • 18.3.9.1. Company Overview
      • 18.3.9.2. Financial Overview
      • 18.3.9.3. Product Portfolio
      • 18.3.9.4. Business Strategies
      • 18.3.9.5. Recent Developments
    • 18.3.10. Santen Pharmaceutical Co., Ltd.
      • 18.3.10.1. Company Overview
      • 18.3.10.2. Financial Overview
      • 18.3.10.3. Product Portfolio
      • 18.3.10.4. Business Strategies
      • 18.3.10.5. Recent Developments
    • 18.3.11. Cipla Limited
      • 18.3.11.1. Company Overview
      • 18.3.11.2. Financial Overview
      • 18.3.11.3. Product Portfolio
      • 18.3.11.4. Business Strategies
      • 18.3.11.5. Recent Developments
    • 18.3.12. Lupin Pharmaceuticals, Inc.
      • 18.3.12.1. Company Overview
      • 18.3.12.2. Financial Overview
      • 18.3.12.3. Product Portfolio
      • 18.3.12.4. Business Strategies
      • 18.3.12.5. Recent Developments
    • 18.3.13. Ocular Therapeutix, Inc.
      • 18.3.13.1. Company Overview
      • 18.3.13.2. Financial Overview
      • 18.3.13.3. Product Portfolio
      • 18.3.13.4. Business Strategies
      • 18.3.13.5. Recent Developments
    • 18.3.14. Novaliq GmbH
      • 18.3.14.1. Company Overview
      • 18.3.14.2. Financial Overview
      • 18.3.14.3. Product Portfolio
      • 18.3.14.4. Business Strategies
      • 18.3.14.5. Recent Developments
    • 18.3.15. ZEXUS PHARMA
      • 18.3.15.1. Company Overview
      • 18.3.15.2. Financial Overview
      • 18.3.15.3. Product Portfolio
      • 18.3.15.4. Business Strategies
      • 18.3.15.5. Recent Developments
    • 18.3.16. Grevis Pharmaceuticals Pvt. Ltd.
      • 18.3.16.1. Company Overview
      • 18.3.16.2. Financial Overview
      • 18.3.16.3. Product Portfolio
      • 18.3.16.4. Business Strategies
      • 18.3.16.5. Recent Developments
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제